Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioNTech SE filings document the disclosures of a foreign private issuer that reports to the SEC primarily through Form 6-K current reports and annual reports on Form 20-F. The records cover interim condensed consolidated financial statements, operating and financial reviews, corporate updates, and exhibit filings related to press releases and investor presentations.
BioNTech’s filings also describe ADS-related capital actions, including repurchase program disclosures for American Depositary Shares representing ordinary shares. Other recurring subjects include annual general meeting invitations and shareholder voting mechanics, governance matters, clinical and regulatory updates for oncology programs, COVID-19 vaccine activity, collaboration-related pipeline information, and material-event disclosures affecting capital allocation and corporate strategy.
BioNTech SE filed a Form 6‑K to inform investors that on October 1, 2025 it hosted its second AI Day together with its artificial intelligence company InstaDeep Ltd. This event is part of BioNTech’s “Innovation Series” and provided an overview of its AI strategy, its AI capabilities, and how AI is applied across BioNTech’s product pipeline and internal processes.
The related investor presentation, offering more detail on these AI initiatives, is furnished as Exhibit 99.1 to the report.
BioNTech SE filed a Form 6-K noting that it and Bristol Myers Squibb have presented interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) in extensive-stage small cell lung cancer. The investigational bispecific antibody targets PD-L1 and VEGF-A and is being evaluated in combination with chemotherapy. According to the attached press release description, the interim Phase 2 data show encouraging antitumor activity in this patient population.
BioNTech entered a materially significant collaboration with Bristol-Myers Squibb to develop and commercialize the investigational bispecific antibody BNT327. Under the amended and restated agreement, BMS will pay $1.5 billion upfront plus $2.0 billion in non-contingent anniversary payments through 2028, and BioNTech is eligible for up to $7.6 billion in additional milestones. The parties will equally share global profits and losses and will generally split development costs equally, with adjusted sharing when one party contributes proprietary assets to a combination trial. BioNTech will initially supply clinical material and lead manufacturing transfer to BMS, after which BMS will assume commercial supply while BioNTech retains the right to supply a percentage of commercial product. Co-exclusive IP licenses and joint governance structures for development and commercialization are established.
BioNTech SE (BNTX) Form 144 notice reports a proposed sale of 500,000 American Depositary Shares through Goldman Sachs & Co. LLC with an approximate aggregate market value of $56,230,000 and an approximate sale date of 09/05/2025. The ADS class shows 237,725,735 shares outstanding. The filing states the 500,000 ADS were originally acquired in a private placement on 01/05/2018 from BioNTech SE and paid in cash. The notice also lists multiple prior sales by AT Impf GmbH during the past three months, including transactions on 06/05/2025 (50,000 ADS), 07/10/2025 (40,000 ADS), and several July 2025 dates down to 4,500 and 500 ADS, each with reported gross proceeds. The filer certifies no undisclosed material adverse information.
BioNTech SE reported that a pivotal Phase 3 trial of its antibody-drug conjugate candidate trastuzumab pamirtecan (BNT323/DB-1303), developed with Duality Biologics, met its primary goal. The study, conducted by DualityBio in China, compares BNT323/DB-1303 with trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have already received trastuzumab and a taxane-based chemotherapy.
At a pre-specified interim analysis, the trial achieved its primary endpoint of progression free survival, meaning patients on BNT323/DB-1303 lived longer without their cancer worsening than those on the comparator. A detailed press release with more information on the results is referenced as an exhibit to this report.
BioNTech SE reports that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for its and Pfizer’s LP.8.1‑adapted monovalent COVID‑19 vaccine, COMIRNATY LP.8.1. The vaccine is now approved for adults aged 65 and older and for individuals aged 5 through 64 who have at least one underlying condition that puts them at high risk for severe COVID‑19. This expands use of the updated mRNA vaccine in key higher‑risk groups in the United States.
Form 144 filing for BioNTech SE (BNTX) shows a proposed sale of 1,774,837 American Depositary Shares representing ordinary shares, with an aggregate market value of $200,024,129.90. The sale is reported through Berenberg Capital Markets LLC on 08/15/2025 and the shares are listed on the Nasdaq Global Select. The filing discloses that the seller acquired the underlying ordinary shares via stock option exercises on 08/09/2024 (918,651 shares) and 11/21/2022 (856,186 shares). The filing reports no sales in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 filed for BioNTech SE (BNTX) reporting a proposed sale of 185,001 American Depositary Shares (ADS) representing ordinary shares. The broker listed is Berenberg Capital Markets LLC with an approximate sale date of 08/15/2025 on Nasdaq Global Select. The aggregate market value of the proposed sale is reported as $20,849,612.70 and the number of shares outstanding is listed as 240,398,724. The securities were acquired on 11/21/2022 through a stock option exercise from BioNTech SE. The filer reports no securities sold in the past three months and includes the standard certification that the seller is not aware of undisclosed material adverse information.
BioNTech announced settlement arrangements resolving U.S. patent litigation with CureVac and related arrangements with GSK and Pfizer. The parties agreed to dismiss U.S. patent claims and BioNTech received a non-exclusive U.S. license (with sublicensing rights) to make, use, sell and import mRNA vaccines for COVID-19 and influenza developed with Pfizer. The deal creates royalty and cash obligations: BioNTech will pay $370 million to GSK and $370 million to CureVac under specified triggers, plus a 1% royalty on U.S. sales of licensed products to each of GSK and CureVac effective January 1, 2025.
Subject to closing of BioNTech’s planned acquisition of CureVac, the company will obtain worldwide non-exclusive licenses, the parties must dismiss non-U.S. claims, BioNTech will pay an additional $130 million to GSK upon certain later conditions, and Pfizer agreed to reimburse BioNTech $80 million plus half of claimed GSK royalties from January 1, 2025 for COVID-19 mRNA products. The company disclaims any admission of liability and highlights transactional and regulatory risks.
Filing: On August 4, 2025, BioNTech SE filed a Form 6-K reporting a development update and its financial results for the three and six months ended June 30, 2025.
Exhibit: The filing states that the interim condensed consolidated financial statements and the operating and financial review and prospects for the three and six months ended June 30, 2025 are attached as Exhibit 99.1 and are deemed filed under Section 18 of the Exchange Act.
Signatures: The report is signed by Ramón Zapata-Gomez, Chief Financial Officer, and Dr. Sierk Poetting, Chief Operating Officer, dated August 4, 2025. The Form 6-K body contains no financial line-item figures; readers are referred to Exhibit 99.1 for detailed results.